{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-129619","form_type":"8-K","ticker":"CGTX","cik":"0001455365","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2024-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.484785+00:00","generated_at":"2026-05-29T01:57:56.685149+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"low","headline":"Cognition Therapeutics releases topline data from Phase 2 COG1201 SHIMMER study","bullets":["Slide presentation on topline results from Phase 2 COG1201 SHIMMER study made available as Exhibit 99.1.","Study evaluates lead candidate for Alzheimer's disease; no specific data points disclosed in the 8-K body.","Filing dated December 18, 2024; presentation likely includes efficacy/safety findings but details are unreadable.","Company undertakes no obligation to update the materials; investor attention should review the full presentation."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-129619","json":"https://secwatch.observer/filing/0001104659-24-129619.json","markdown":"https://secwatch.observer/filing/0001104659-24-129619.md","text":"https://secwatch.observer/filing/0001104659-24-129619.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465924129619/0001104659-24-129619-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465924129619/tm2431405d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T01:57:56.685149+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}